E
Lunai Bioworks Inc. LNAI
$1.02 -$0.15-12.82% NASDAQ
Recommendation
Prev Close
$1.17
Volume
3,974,676
Avg Vol (90D)
2,088,467
Market Cap
$27.12M
Dividend & Yield
--
52-Week Range
$0.81 - $21.00
P/E (TTM)
--
EPS (TTM)
-$10.46
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Top Biotech Stocks To Follow Now - November 5th
11/6/2025 - MarketBeat
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in ...
11/5/2025 - GuruFocus
Lunai Bioworks announces regression of tumors with immune cell therapy
11/5/2025 - The Fly
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
11/5/2025 - PR Newswire
Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds
10/30/2025 - GuruFocus
Lunai Bioworks Faces Nasdaq Non-Compliance Notice
10/30/2025 - TipRanks Financial Blog
Lunai Bioworks announces early results from AI-based platform
10/30/2025 - The Fly
Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds
10/30/2025 - ACCESS Newswire
Lunai Bioworks Regains Nasdaq Compliance in October 2025
10/16/2025 - TipRanks Financial Blog
Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
10/16/2025 - GuruFocus
Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics
10/16/2025 - ACCESS Newswire
Lunai Bioworks regains compliance with Nasdaq minimum bid price rule
10/16/2025 - The Fly
Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
10/16/2025 - ACCESS Newswire
Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline
10/6/2025 - GuruFocus
Lunai Bioworks launches AI-powered Alzheimer's Disease program
10/6/2025 - The Fly
Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline
10/6/2025 - ACCESS Newswire
Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense
9/30/2025 - ACCESS Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$18.42M
EBIT (TTM)
-$18.55M
Net Income (TTM)
-$178.01M
Balance Sheet
Total Assets (Q)
$8.23M
Total Debt (Q)
$10.45M
Total Liabilities (Q)
$29.58M
Book Value Per Share (Q)
-$1.20
Cash Flow
Cash from Operations (TTM)
-$7.87M
Cash from Investing (TTM)
-$500.00K
Cash from Financing (TTM)
$8.38M
Net Change in Cash (TTM)
-$127.80K
Filings
Filing Date
Monday, September 29, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
0.76
7-Day Total Return
-1.92%
30-Day Total Return
-27.45%
60-Day Total Return
-57.76%
90-Day Total Return
-62.50%
Year to Date Total Return
-86.63%
1-Year Total Return
-83.69%
2-Year Total Return
-96.34%
3-Year Total Return
-94.36%
5-Year Total Return
-96.66%
52-week Low
Nov 03, 2025 - $0.81
52-week High
Dec 09, 2024 - $21.00
Valuation
Market Cap
$27.12M - Nano Cap
Enterprise Value
$37.08M
Price/Sales (TTM)
--
Price/Book (Q)
-0.97
Dividends and Shares
Shares Outstanding
17.61
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.lunaibioworks.com
Phone Number
305 918 1980
Address
2080 Century Park East
Los Angeles, CA 90067
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments... more
NASDAQ 11/06/2025 4:00PM Eastern Quotes delayed